Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Synairgen (SNG)

Price 2.60p on 30-01-2025 at 17:30:06
Change 0.06p 2.67%
Buy 2.60p
Sell 2.01p
Buy / Sell SNG Shares
Last Trade: Unknown 7,224.00 at 2.00p
Day's Volume: 248,763
Last Close: 2.305p
Open: 2.01p
ISIN: GB00B0381Z20
Day's Range 2.01p - 2.60p
52wk Range: 1.71p - 10.00p
Market Capitalisation: £29m
VWAP: 2.38714p
Shares in Issue: 1,103m

Recent Trades History Synairgen (SNG)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 7,224 2.00p OTC Trade
16:17:00 - 30-Jan-25
Sell* 24,433 2.045p Ordinary
16:26:51 - 30-Jan-25
Sell* 20,452 2.01p SI Trade
16:17:47 - 30-Jan-25
Sell* 520 2.01p SI Trade
16:17:36 - 30-Jan-25
Buy* 140,877 2.60p Suspected BUY Trade
16:17:36 - 30-Jan-25
Sell* 463 2.039p Ordinary
16:03:48 - 30-Jan-25
Sell* 60 2.039p Ordinary
15:17:51 - 30-Jan-25
Sell* 13,000 2.068p Ordinary
15:13:44 - 30-Jan-25
Sell* 2,300 2.039p Ordinary
14:33:08 - 30-Jan-25
Unknown* 321 2.01p OTC Trade
14:13:49 - 30-Jan-25

Share Price History for Synairgen

Time period:
to
Date Open High Low Close Volume

Share News for Synairgen

AIM WINNERS & LOSERS: Tiger Royalties to buy Bixby Technologies

20th Dec 2024 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More

UK shareholder meetings calendar - next 7 days

3rd Oct 2024 15:46

Read More

EARNINGS: Hansard Global profit down; Flowtech cuts outlook

26th Sep 2024 19:33

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Synairgen slashes costs and focuses on small hospital trials

27th Jun 2024 12:04

Synairgen PLC - South Hampton, England-based drug discovery and development company focused on combatting respiratory disease - In 2023, pretax loss narrowed to GBP9.7 million from GBP20.1 million a year prior. No revenue generated. Research & Development expenditure down 56% to GBP6.5 million from GBP14.9 million. Other administrative expenses fell 30% to GBP3.8 million from GBP5.4 million. Cash and cash equivalents held at GBP10.5 million, down 34% from GBP15,9 million. Read More

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

7th May 2024 09:51

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday: Read More

FTSE 100 Latest
Value8,646.88
Change89.07

Login to your account

Forgot Password?

Not Registered